# Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

> **NCT06959706** · PHASE1 · RECRUITING · sponsor: **Tagworks Pharmaceuticals BV** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** TGW101

## Key facts

- **NCT ID:** NCT06959706
- **Lead sponsor:** Tagworks Pharmaceuticals BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-07
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06959706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06959706, "Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06959706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*